FoundationOne CDx
Tissue-based comprehensive genomic profiling and indication-specific companion diagnostic for solid tumors.
- Developer
- Foundation Medicine
- Intended use
- Other
- Cancer scope
- Not reported
- Specimen
- FFPE tumor tissue
- Molecular modality
- DNA mutation
- Current version
- Current FoundationOne CDx commercial lineage as of 2026-09
- Evidence context
- 1 structured studies · 0 indexed performance results · 5 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.